Insights into a Rare Clinical Phenomenon:

Isolated Native Valve Endocarditis After Prosthetic Valve Implantation

Selective Native Valve Endocarditis Following Transcatheter and Surgical Implants

Sujoy Khasnavis MD[1], Majd Alhuarrat MD[1], Caroline Delbourgo Patton MA, MSLIS[2],

Shaunak Mangeshkar MD[1], Robert Faillace MD[1], Michael Grushko MD[1]

[1]Jacobi-North Central Bronx Hospital and Medical Center, Bronx NY

[2]D. Samuel Gottesman Library, Albert Einstein College of Medicine, Bronx, NY

Address for correspondence:

Sujoy Khasnavis, 646-761-3081, sujoy.khasnavis@gmail.com

111 East 210th Street Bronx, NY 10467

Conflict of interest disclosure: The authors declare no conflict of interest

Funding disclosure: This research did not receive any specific grant from funding agencies in the public commercial, or non-for-profit sectors

Ethics declaration: Not applicable

Word count: 1645

Isolated Native Endocarditis Prosthetic Valve Implantation

Key Points

Question: What are the incidence, associations, predictors, implicated causes, and outcomes of selectiveanc isolated native valve endocarditis following prosthetic valve implantation?

Findings: This systematic review found that isolated native valve endocarditis was reported most frequentl after transcatheter aortic valve implants and particularly in mitral valves. Infrequently, isolated native endocarditis has also been reported in right heart valves and after surgical aortic valve implants. Diabetes ar pulmonary disease are associated with isolated native endocarditis after transcatheter implants.

Meaning: The development of isolated native mitral valve endocarditis should be closely screened fo diabetic and pulmonary patients with transcatheter aortic valve implants. This phenomenon needs further s in non-aortic, non-transcatheter, and non-mitral endocarditis populations. Moreover, patients with this endocarditis require close long term follow up as mortalities after hospitalization are significantly higher th hospital.

Isolated Native Endocarditis Prosthetic Valve Implantation

Abstract

Introduction: Prosthetic valve endocarditis (PVE) is a known complication of prosthetic valve implant (PVI). The incidence of selective native valve endocarditis without concurrent PVE, or isolated native v endocarditis (INVE), is much lower and largely unheard of in literature.

Methods: We examine here the specific circumstances in which INVE manifests as well as management complications of this rare form of endocarditis. A systematic review of four major databases was carried o identify INVE and PVE cases after various PVIs. INVE was compared to PVE across categories such as pa demographics, method and type of PVI prior to endocarditis, pathogen type, management, and outcomes.

Results: INVE comprised 18.2 % of valvular endocarditis cases after transcatheter aortic valve implant (TAVI) and 6.5 % of valvular endocarditis cases after surgical aortic valve implantation (SAVI). In the T group, mean age of the INVE cohort was 79.5 +- 5 years and it was observed more frequently among m Prior to most INVE cases, TAVI had been performed by transfemoral route. INVE was more closely link diabetes (DM) and chronic obstructive pulmonary disease (COPD) than TAVIE (transcatheter aortic v implant endocarditis). INVE was less closely linked to chronic kidney disease (CKD) than TAVIE. C positive infection rates were similar between the groups. Surgery was done less frequently after INVE TAVIE. Compared to TAVIE, INVE mortalities were more likely to occur at follow up and were linked to l failure, renal failure, and septic shock. Total long term mortalities were similar between the two groups.

Conclusion: INVE makes up a measurable proportion of endocarditis cases after TAVI and sh characteristics, predictors, pathogens, and outcomes linked to TAVIE. Compared to TAVIE, INVE is r closely linked to DM and COPD and less to CKD. It manifests more on mitral valves than right heart valves presents higher rates of delayed mortality. Given INVE's long term mortality and ability to manifest on diff valves, thorough cardiac evaluation and close long term follow up should be considered if endocardit

suspected after TAVI. Non-mitral INVE and surgical implant based INVE are less frequently reported on warrant further investigation.

Keywords: Isolated native valve endocarditis, transcatheter aortic valve implantation, prosthetic v implantation, mitral endocarditis, right heart endocarditis

Abbreviations: IE = infective endocarditis, INVE = isolated native valve endocarditis, PVE = prosthetic v endocarditis, NVE = native valve endocarditis, PVI = prosthetic valve implant, TAVI = transcatheter a valve implantation, TAVIE = transcatheter aortic valve implant endocarditis, SAVI = surgical aortic v implantation, SAVIE = surgical aortic valve implant endocarditis, DM = diabetes mellitus, COPD = chr obstructive pulmonary disease, CKD = chronic kidney disease

Introduction

Prosthetic valve endocarditis (PVE) is an established complication of mechanical and bioprosth valve placement[1,2]. Generally, infective endocarditis (IE) has a predilection for prosthetic valves over na valves given the nidus that the prostheses provide for bacterial attachment and infection[3,4]. PVE also carr higher mortality rate than does native valve endocarditis (NVE). The incidence of NVE subsequent to PVE also been described and is known to carry a poorer prognosis than isolated PVE[4,8]. In the setting of PVI development of isolated native valve endocarditis (INVE) without PVE is an unusual phenomenon. S retrospective reviews have described instances of mitral INVE after PVIs[1,3,6,9,12]. Case reports have described instances of mitral and aortic INVE after atypical bacterial infections[18,19,20]. A comprehensive rev detailing the specifics of INVE has not been performed in prior studies however. This review provide summary of the literature on INVE after various PVIs including transcatheter valve implantation and sur valve implantation with the purpose of understanding the patient characteristics, potential contribu

management strategies, and outcomes associated with this rare and unusual type of IE.

Methods

Search strategy

A systematic review of studies reporting INVE was performed across databases of Pubmed, Eml Cochrane Library, and Web of Science. Search terms encompassed PVI types including transcatheter v implants and surgical valve implants as well as PVE and NVE. Table 1 shows the complete search criteria.

Definition and Distinction of Valvular Endocarditis

The definition and diagnosis of IE adopted in our review were symptoms/signs of IE with evidence c organism growth in serial blood cultures and echocardiographic evidence of any of the following lesions in t endocardium - vegetation, abscess, aneurysm, fistula, pseudoaneurysm, or dehiscence. Distinction between PVE, NVE, and nonvalvular IE was made according to whether IE after PVI was reported on a prosthetic va only versus prosthetic and native valve versus native valve only versus nonvalvular locations. This distinctio was used to identify TAVIE (transcatheter aortic valve implant endocarditis), SAVIE (surgical aortic valve implant endocarditis), nonaortic prosthetic IE, combined PVE and NVE, INVE, and nonvalvular IE.

Study selection

Figure 1 shows the PRISMA strategy for screening and exclusion using Covidence. All aut were aware of journal titles, authors, and sites. No limits were placed on study date or design except conference abstracts, editorials, and commentaries were excluded. Case reports, case series, and meta anal where included were done for reference purposes only and not for data analyses. Non-English studies excluded. Review and cohort articles describing outcomes/results/events after PVI were included. A screening of abstracts, full texts were reviewed and, if meeting the criteria for INVE, were included for

extraction. References in these texts were also examined and included for data extraction if they met the cri for INVE.

Data extraction

Articles in the final set were examined and data on several categories were identified. Specificall incidence after PVI, age groups affected, gender affected, comorbidities, PVI type, method of PVI, patho left ventricular ejection fractions, treatment type, follow up periods, mortality rates, and causes of mort were determined for PVE and INVE groups. Combined PVE and NVE cases were included in the PVE gr Nonvalvular IE cases were excluded. Data was acquired directly through articles, contact with the authors o articles, and the IE after TAVR registry[5]. All data are available in the tables with the manuscript. All aut contributed to data acquisition.

Results

Search outcomes

The search yielded 952 studies after removal of duplicates in Covidence. In these 952 studies, abstra that described the outcomes of PVI were identified and moved into full text review. Out of 196 full texts on outcomes, 16 matched the criteria for INVE. These studies were manually reviewed for INVE populations f the same registries. References in these studies were also reviewed. Ultimately, INVE cases reporting non TAVIs and non SAVIs were excluded from data analyses since very few cases were identified. INVE cases from 8 studies on TAVI and SAVI were included in the final analysis (Table 2). These studies comprised of retrospective reviews and complete prospective cohorts. A p value less than 0.05 was considered significant

Risk of bias

Isolated Native Endocarditis Prosthetic Valve Implantation

All 8 articles were of good quality based on assessment of selection, comparability, and expo categories in the Newcastle Ottawa assessment. However, some data on the categories of interest to our s were not reported; these data were marked as “unknown” or "?"in Tables 2 and 4. The INVE group represented in all studies. The studies obtained patient and outcome information from institutional me records. All studies assessed outcomes and ensured adequate follow-up. Follow-up time was sufficien outcomes to occur in all cohorts. Notably, one study drew data from an international registry consistin multicenter databases while remaining studies drew data from unicenter databases. The discrepancie population selection and size raise the possibility that associations close to cutoff for significance ($p < 0$ may be stronger or weaker if comparable populations are analyzed. Moreover, associations that are insignif ($p > 0.05$) may also be different if similar populations are analyzed.

INVE after TAVI

INVE was observed in 119/645 (18.4 %) cases of valvular IE after TAVI. The mean age for the I group was 79.5 +- 5 years and comparable to the TAVIE group (Table 2). In both INVE and TAVIE, cases more frequent in males at 56.3 % and 55.5 % respectively. Comorbidity rates in INVE and TAVIE were si except that diabetes (DM) was present in 40.3 % INVE vs 30.4 % TAVIE (OR 1.55, CI 1.03 - 2.33, p = 0.0 Chronic obstructive pulmonary disease (COPD) was present in 29.4 % INVE vs 20.2 % TAVIE (OR 1.6 1.05 - 2.58, p = 0.027). Chronic kidney disease (CKD) was present in 32.8 % INVE vs 46.2 % TAVIE (OR CI 0.37 - 0.86, p = 0.008).

Transfemoral access was utilized for TAVI prior to most cases of INVE and TAVIE wit insignificantly higher rate in the INVE group. Beta lactam antibiotic prophylaxis was carried out in at least of both groups with other antibiotics contributing the remaining 20%. No concurrent infections were not either group. Moreover, there were few instances of prior endocarditis or prior valvular procedures in e

group and where present occurred at comparable rates. Mean left ventricular ejection fraction (LVEF) in Il was 56 +-11.5 %, similar to TAVIE. Corevalves were more frequently associated with INVE than TAVI 56.3 % vs 45.4 % (OR = 1.55, CI 1.04 - 2.31, p = 0.032). The valvular distributions of INVE were 87 (73.1%) on mitral valves and 32/119 (26.9%) on right heart valves. The specific right heart valve locatio the latter were not identifiable. Infections in INVE and TAVIE were from gram positive flora suc staphylococci, streptococci, and enterococci at comparable rates. The sources of these pathogens were unkr in most of the cases, although gastrointestinal and urinary tract were considered likely points. INVE c required surgery less frequently than did TAVIE cases at 7.6 % vs 24.7 % (RR = 0.31, CI 0.16 - 0.58, p < 0.

Ultimately, TAVIE and INVE cases were followed for approximately 2 years. INVE mortalities lower in hospital at 21.0 % INVE vs 32.3 % TAVIE (RR 0.65, CI 0.45 - 0.94, p = 0.016). INVE morta were higher at follow up at 30.3 % INVE vs 20.7 % TAVIE (RR 1.47, CI 1.07 - 2.03, p = 0.021). Mortality due to any particular cause were similar across both groups in hospital and at follow up (Table 3).

INVE after SAVI

INVE was observed in 9/138 (6.5 %) cases of valvular IE after SAVI. The mean age for the SA group was 59.9 ± 15.8 years and for INVE group was 64.4 ± 3.8 years (Table 4). Cases were reported r frequently in males than females. Comorbidities observed with both SAVIE and INVE included diab hypertension, heart failure, mitral regurgitation, aortic regurgitation, prior endocarditis, prior valve surgery, malignancy. In the SAVIE group, staphylococcus was source of infection in 44% of cases and sur management was required in about one third of the cases. Mortality rates in the SAVIE group were 18 hospital and 7 % at follow up due to endocarditis complications. Data on the INVE group was limited. It sh be noted however that in 2 of the 9 INVE cases, one was a tricuspid INVE associated with rheumatic dis and the source of infection was the uninfected SAVI. The other case was a mitral INVE with infection suspe

from cardiac catheterization and uninfected SAVI. A formal statistical analysis of the categories of intere the SAVI INVE and SAVIE groups was not possible given the small sizes and incomplete data on the group

One instance of mitral INVE after SAVI that was not included in the data analysis was a case report Brucella infection[19]. The patient was 58 year old male with history of severe aortic stenosis requiring S. Details regarding antibiotic prophylaxis, surgical approach, prosthesis type, ejection fraction, and suspe cause of INVE were not provided. The patient was treated with antibiotic therapy alone without subsec INVE complications and was alive at 1 year follow up.

INVE in non aortic prostheses

A few studies in our search reported INVE subsequent to non-aortic prostheses. One study describ single case of mitral INVE subsequent to transcatheter pulmonic valve replacement[8]. In this retrospective si center study, the patient was a 54 year old female with history of end stage renal disease on dialysis, pulm stenosis, and pulmonic endocarditis requiring Sapien 3 prosthetic implantation. The prosthetic valve was fr infection and the dialysis line was determined to be the source for mitral INVE. The pathogen was methi sensitive staph aureus treated with antibiotics and surgical mitral replacement. The prognosis was good patient was alive after 2 years of follow up.

Two studies reported on aortic INVE subsequent to mitral PVI. One study was a cohort follo patients after mitral surgical PVI[12]. A total of 9 patients were identified with 8 developing endocarditis o mitral PVI and 1 developing aortic INVE. The details on this aortic INVE patient including the patient's gender, comorbidities, surgical approach of PVI, PVI type, source of INVE, infecting pathogen, complications after treatment of INVE could not be identified. However, it was known that the patient treated with antibiotic therapy alone without surgery. Moreover, the patient was followed for 10 years INVE developing 8 years after PVI and died at follow up from endocarditis complications.

The second study was a case report involving a 42 year old male with mitral PVI that had been dc years before aortic INVE[18]. Comorbidites included aortic valve regurgitation, rhemautic mitral disease, mitral stenosis. He had undergone a St. Jude procedure of the mitral valve. The prosthesis type was unknov was the source of INVE. The pathogen involved was Corynebacterium diphtheriae and he was treated combined antibiotics + surgery. No complications were noted after aortic INVE and he was alive at follow u

Discussion

This review study showcases that INVE has been reported and well studied in native mitral valves TAVI. While INVE in non mitral locations and INVE subsequent to non TAVI prostheses have also reported in literature, these groups have not been studied as extensively. Given this discrepancy, it is surprising that the INVE associations and outcomes here reflect what has been previously reported on m INVE after TAVI[1]. The cumulative findings do show that comorbidities such as DM and COPD were r closely associated with INVE than TAVIE. Based on these findings, it is plausible to say that t comorbidities may present a higher risk for mitral IE due to their high propensity for cardiopulmo complications[25]. However the findings could be coincidental and need to be validated by using a larger Il population and ruling out confounders based on raw data. On the other hand, the weaker correlation with C is consistent with data showing that TAVIE is closely associated with CKD[5]. This correlation may explain renal failure was a significant cause of mortality in the TAVIE group. However, the number of patients TAVIE and renal failure who initially had CKD was not available for analysis in our study and the true exte this association would need to be explored further as well. Among other categories, the use of self expan Corevalve TAVIs and the resulting mitral INVE was consistent with prior study findings which demonst the higher likelihood of mitral IE compared to TAVIE with the use of Corevalves[1]. As TAVIE presents a hi likelihood of serious complications early on, the study supports the expected finding that mortalities were hi in hospital compared with INVE. The converse finding of higher INVE mortality at follow up coul

explained on the basis that conservative therapy may be less effective over time when the initial infectior had opportunity to spread systemically and lead to complications. Moreover, TAVIE is treated ı aggressively with surgery on initial presentation and patients that survive may be less likely to have long complications as compared to conservatively managed INVE patients. Appropriate management of INV therefore a subject of future study.

Regarding non mitral INVE after TAVI and mitral INVE after non TAVI, more investigations needed. This review identified TAVI INVE cases that occurred as right heart INVE but the size of this g was insufficient for a subgroup analysis. Moreover, the number of SAVI INVE cases was even more lin along with the data on this group. The incidence of these cases does demonstrate however that there alternate mechanisms for mitral and non mitral INVE in the setting of TAVIs, SAVIs, and other F Moreover, pathogens also seem to play a role in INVE as was suggested in studies showing that E coli selectively target native mitral valves in the presence of prosthetic valves[20].

Thus far, very few reviews have holistically examined the drivers and outcomes of INVE. Such rev would have to identify many patients with this rare form of IE and acquire data on each individual patie process that would be extremely time consuming. On the other hand, smaller studies can more feasibly acc individual patient data on categories of interest, but do have not enough power to make significant associat Our review is the first to attempt a comprehensive analysis of this unusual phenomenon. It prelimin suggests that the development of INVE after PVI is closely linked to comorbidity type, PVI type, proce aspects of PVI, and pathogen type. It also indicates that the prognosis for INVE correlates with the presen heart failure, renal failure, and septic shock. The significance of surgical vs medical management in long survival is unclear and warrants future investigation.

Limitations

There were some notable limitations in our study. First, only 16 studies fit the criteria for inclu Among TAVI studies, data was frequently acquired from the IE After TAVI Registry which after remov duplicates limited the size of the TAVI INVE population. Moreover, the size of the SAVI INVE population extremely small and this prevented any type of analysis on that subgroup. Overall, the discrepancies in t groups created the impression that INVE is a TAVI associated phenomenon when in reality data is lacking true comparison of the different PVIs. To this end, establishing the incidence, associations, and predictor INVE requires more data and a larger population of INVE patients.

A second limitation in our analysis was the challenge of accounting for confounders. Although t were no concurrent infections and antibiotic prophylaxis was similar in TAVIE and TAVI INVE gro performing a stratified analysis was challenging without data to compare the categories of interest. This c potentially change the significance of the associations seen in the study and would need to addressed using r raw data.

Another limitation involved the nature of the included studies themselves. One study was a multic review made up of a cohort that represented several international patient populations. All other studies c data from unique hospital centers, each representing different patient populations. The final analysis requ making a generalization about the associations in different patient populations and these associations ma different if comparable populations had been available for study.

Lastly, our study could not determine if studies excluded during full text review had unrepo instances of INVE. As PVE is more common and studied more extensively than INVE, unreported INVE could strengthen or weaken the associations in our study. Future research should be aimed towards acqu more explicit data on INVE from studies that have reported on the phenomenon as well as studies that have reported on the phenomenon.

Conclusion

Isolated Native Endocarditis Prosthetic Valve Implantation

INVE is a complication frequently observed after transfemoral TAVIs among older patients. Dia and COPD patients appear to have a higher risk of developing this rare form of valvular IE, notably on n valves. Gram positive skin pathogens are frequently involved in INVE. Mortality in INVE is more comm those who develop renal failure, heart failure, and septic shock, particularly during long term follow up. incidences, contributors, associations, and outcomes of INVE after SAVI and non aortic PVI are less established and warrant future study.

References

1. Panagides V, Del Val D, Abdel-Wahab M et al. Mitral Valve Infective Endocarditis after Trans-Cat Aortic Valve Implantation. Am J Cardiol. 2022 Jun 1;172:90-97. doi: 10.1016/j.amjcard.2022.02.034. 2022 Apr 3. PMID: 35387738.
2. Tinica G, Tarus A, Enache M et al. Infective endocarditis after TAVI: a meta-analysis and systematic re of epidemiology, risk factors and clinical consequences. Rev Cardiovasc Med. 2020 Jun 30;21(2):263- doi: 10.31083/j.rcm.2020.02.68. PMID: 32706214.
3. Yun JJ, Saleh OA, Chung JW et al. Cardiac Operations After Transcatheter Aortic Valve Replacement. Thorac Surg. 2022 Jul;114(1):52-59. doi: 10.1016/j.athoracsur.2021.10.022. Epub 2021 Nov 17. P 34800488.
4. Mangner N, Leontyev S, Woitek FJ Cardiac Surgery Compared With Antibiotics Only in Pat Developing Infective Endocarditis After Transcatheter Aortic Valve Replacement. J Am Heart Assoc. Sep 4;7(17):e010027. doi: 10.1161/JAHA.118.010027. PMID: 30371173; PMCID: PMC6201426.
5. Regueiro A, Linke A, Latib A, et al. Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. *JAMA.* 2016;316(10):1083–1092. doi:10.1001/jama.2016.12347.
6. Croon SI, Angkasuwan A, van Straten AH et al. Surgical treatment and long-term outcome of

aortic valve endocarditis with periannular abscess. Neth Heart J Jun 2020;28(6):345-353.

7. Martín-Dávila P, Fortún J, Navas E et al. Nosocomial endocarditis in a tertiary hospital: an increasing trend in native valve cases. Chest Aug 2005;128(2):772-9. 2005 Aug.

8. Korem M, Israel S, Gilon D et al. Epidemiology of infective endocarditis in a tertiary-center in Jerusale 3-year prospective survey. Eur J Intern Med Jul 2014;25(6):550-5. 2014 Jul.

9. Solari S, Mastrobuoni S, De Kerchove L et al. Over 20 years experience with aortic homograft in aortic v replacement during acute infective endocarditis. Eur J Cardiothorac Surg Dec 2016;50(6):1158-1164. 2016

10. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H et al. Infective endocarditis after transcatheter a valve implantation: results from a large multicenter registry. Circulation. 2015 May 5;131(18):1566-74. 10.1161/CIRCULATIONAHA.114.014089. Epub 2015 Mar Erratum in: Circulation. 2020 Jun 2;141(22):e PMID: 25753535.

11. Lluri G, Levi DS, Miller E, Hageman A, Sinha S, Sadeghi S Incidence and outcome of infe endocarditis following percutaneous versus surgical pulmonary valve replacement. Catheter Cardiovasc In 2018 Feb 1;91(2):277-284. doi: 10.1002/ccd.27312. Epub 2017 Sep 12. PMID: 28895275.

12. Sheikh AM, Elhenawy AM, Maganti M et al. Outcomes of surgical intervention for isolated active m valve endocarditis. J Thorac. Cardiovasc Surg Jan 2009;137(1):110-6. 2009 Jan.

13. Scisło P, Grodecki K, Wilimski R et al. Different types of endocarditis after transcatheter aortic v implantation. Echocardiography Jun 2019;36(6):1132-1138. 2019 Jun.

14. Martínez-Sellés M, Bouza E, Díez-Villanueva P et al. Incidence and clinical impact of infe endocarditis after transcatheter aortic valve implantation. EuroIntervention Feb 2016;11(10):1180-7. 2016 F

15. Mangner N, Woitek F, Haussig S et al. Incidence, Predictors, and Outcome of Patients Developing Infe Endocarditis Following Transfemoral Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016 21;67(24):2907-8. doi: 10.1016/j.jacc.2016.03.588. PMID: 27311532.

16. Mentias A, Girotra S, Desai MY et al. Incidence, Predictors, and Outcomes of Endocarditis A Transcatheter Aortic Valve Replacement in the United States. JACC Cardiovasc Interv. 2020 14;13(17):1973-1982. doi: 10.1016/j.jcin.2020.05.012. PMID: 32912457; PMCID: PMC7490767.

17. Del Val D, Abdel-Wahab M, Mangner N et al. Stroke Complicating Infective Endocarditis A Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology May 2021;77(18):2276-2287. 2021 May 11.

18. Pachirat O, Kaewkes D, Pussadhamma B, Watt G Corynebacterium diphtheriae Native Aortic V Endocarditis in a Patient With Prosthetic Mitral Valve: A Rare Presentation. Cardiol Res. 2018 Oct;9(5): 317. doi: 10.14740/cr741w. Epub 2018 Oct 7. PMID: 30344830; PMCID: PMC6188043.

19. Katircibaşi MT, Koçum HT, Cölkesen AY, Tekin A, Sezgin AT. Management of Brucella endocarditi native mitral valve in a patient with prosthetic aortic valve: a case report. Int J Cardiol. 2008 26;129(2):300-1. doi: 10.1016/j.ijcard.2007.06.058. PMID: 17659796.

20. Akuzawa N, Kurabayashi M Native valve endocarditis due to Escherichia coli infection: a case report review of the literature. BMC Cardiovasc Disord. 2018 Oct19;18(1):195. doi: 10.1186/s12872-018-09 PMID: 30340526; PMCID: PMC6194693.

21. Mangner N, del Val D, Abdel-Wahab M, Crusius L, Durand E, Ihlemann N, et al. Surgical Treatme Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation. J Am Coll Cardiol. Mar 1;79(8):772-785. doi: 10.1016/j.jacc.2021.11.056. PMID: 35210032.

22. Latib A, Naim C, De Bonis M, Sinning JM, Maisano F, Barbanti M, et al. TAVR-associated prost valve infective endocarditis: results of a large, multicenter registry. J Am Coll Cardiol. 2014 Nov 25;64(20):2176-8. doi: 10.1016/j.jacc.2014.09.021. PMID: 25457406.

23. Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, et al Prosthetic V Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials. Circulation. 2019 10;140(24):1984-1994. doi: 10.1161/CIRCULATIONAHA.119.041399. PMID: 31690104.

24. Bjursten H, Rasmussen M, Nozohoor S, Götberg M, Olaison L, Rück A, et al Infective endocarditis transcatheter aortic valve implantation: a nationwide study. Eur Heart J. 2019 Oct 14;40(39):3263-3269. 10.1093/eurheartj/ehz588. PMID: 31433472; PMCID: PMC6911164.

25. Biezma MI, Muñoz P, De la Villa S, Fariñas-Álvarez MC, Arnáiz de Las Revillas F, Gutierrez-Carrete De Alarcón A, Rodríguez-García R, Llopis J, Goenaga MÁ, Gutierrez-Villanueva A, Plata A, Vida Martínez-Sellés M, On Behalf Of Games. Infective Endocarditis in Diabetic Patients: A Different Profile Prognostic Consequences. J Clin Med. 2022 May 9;11(9):2651. doi: 10.3390/jcm11092651. PMID: 35566 PMCID: PMC9103728.

Tables

Table 1. Search criteria in Pubmed, Embase, Cochrane, and Web of Science databases

Database	**PubMed**	
Line #	**Search Terms**	**Results**
1	“native valve endocarditis”[tiab] OR “NVE”[tiab] OR “native endocarditis”[tiab:~2]	1,625
2	ive” AND (“mitral valve endocarditis”[tiab] OR “aortic valve endocarditis”[tiab] OR id valve endocarditis”[tiab] OR “pulmonary valve endocarditis”[tiab] OR “pulmonic locarditis”[tiab] OR “infective endocarditis”[tiab] OR “infectious endocarditis”[tiab] OR “bacterial endocarditis”[tiab])	1,763
3	#1 OR #2	2,398
4	Heart Valve Prosthesis"[Mesh] OR "Heart Valve Prosthesis Implantation"[Mesh] OR osthetic valve”[tiab:~2] OR “valve replacement”[tiab] OR “transcatheter aortic valve nent”[tiab] OR “TAVR”[tiab] OR “transcatheter aortic valve implantation”[tiab] OR VI”[tiab] OR "transcatheter tricuspid valve replacement"[tiab] OR "TTVR"[tiab] OR eter pulmonary valve replacement”[tiab] OR “TPVR”[tiab] OR "transcatheter mitral cement”[tiab] OR "transcatheter mitral valve implantation”[tiab] OR “surgical aortic lacement”[tiab] OR “SAVR”[tiab] OR “surgical pulmonary valve replacement”[tiab] VR”[tiab] OR "surgical mitral valve replacement"[tiab] OR "surgical tricuspid valve replacement"[tiab] OR “homograft valve replacement”[tiab]	81,620
5	#3 AND #4	1,153
6	#5 NOT (case reports[pt] OR editorial[pt] OR letter[pt] OR comment[pt])	815
Filters	English-language only	680
erall search	((("native valve endocarditis"[Title/Abstract] OR "NVE"[Title/Abstract] OR "native endocarditis"[Title/Abstract:~2] OR ("native"[All Fields] AND ("mitral valve ndocarditis"[Title/Abstract] OR "aortic valve endocarditis"[Title/Abstract] OR "tricuspid valve rditis"[Title/Abstract] OR "pulmonary valve endocarditis"[Title/Abstract] OR "pulmonic valve endocarditis"[Title/Abstract] OR "infective endocarditis"[Title/Abstract] OR "infectious ndocarditis"[Title/Abstract] OR "bacterial endocarditis"[Title/Abstract]))) AND ("Heart Valve nesis"[MeSH Terms] OR "Heart Valve Prosthesis Implantation"[MeSH Terms] OR "prosthetic lve"[Title/Abstract:~2] OR "valve replacement"[Title/Abstract] OR "transcatheter aortic valve replacement"[Title/Abstract] OR "TAVR"[Title/Abstract] OR "transcatheter aortic valve implantation"[Title/Abstract] OR "TAVI"[Title/Abstract] OR "transcatheter tricuspid valve replacement"[Title/Abstract] OR "TTVR"[Title/Abstract] OR "transcatheter pulmonary valve replacement"[Title/Abstract] OR "TPVR"[Title/Abstract] OR "transcatheter mitral valve ent"[Title/Abstract] OR "transcatheter mitral valve implantation"[Title/Abstract] OR "surgical valve replacement"[Title/Abstract] OR "SAVR"[Title/Abstract] OR "surgical pulmonary valve replacement"[Title/Abstract] OR "SPVR"[Title/Abstract] OR "surgical mitral valve	

Isolated Native Endocarditis Prosthetic Valve Implantation

	ent"[Title/Abstract] OR "surgical tricuspid valve replacement"[Title/Abstract] OR "homograft lacement"[Title/Abstract])) NOT ("case reports"[Publication Type] OR "editorial"[Publication ype] OR "letter"[Publication Type] OR "comment"[Publication Type])) AND (english[Filter])

Database	Embase	
Line #	**Search Terms**	**of Results**
1	‘native valve endocarditis’:ti,ab OR ‘NVE’:ti,ab OR ‘native endocarditis’:ti,ab	1,347
2	ND ('infective endocarditis'/mj OR ‘mitral valve endocarditis’:ti,ab OR ‘aortic valve endocarditis’:ti,ab OR ‘tricuspid valve endocarditis’:ti,ab OR ‘pulmonary valve rditis’:ti,ab OR ‘pulmonic valve endocarditis’:ti,ab OR ‘infective endocarditis’:ti,ab OR ‘infectious endocarditis’:ti,ab OR ‘bacterial endocarditis’:ti,ab)	2,746
3	#1 OR #2	3,406
4	e replacement'/exp/mj OR 'heart valve prosthesis'/mj OR 'aortic valve prosthesis'/mj 'mitral valve prosthesis'/mj OR 'pulmonary valve prosthesis'/mj OR 'tricuspid valve nesis'/mj OR ‘prosthetic valve’:ti,ab OR ‘valve replacement’:ti,ab OR ‘transcatheter aortic valve replacement’:ti,ab OR ‘TAVR’:ti,ab OR ‘transcatheter aortic valve tion’:ti,ab OR ‘TAVI’:ti,ab OR ‘transcatheter tricuspid valve replacement’:ti,ab OR R’:ti,ab OR ‘transcatheter pulmonary valve replacement’:ti,ab OR ‘TPVR’:ti,ab OR ‘transcatheter mitral valve replacement’:ti,ab OR ‘transcatheter mitral valve n’:ti,ab OR ‘surgical aortic valve replacement’:ti,ab OR ‘SAVR’:ti,ab OR ‘surgical pulmonary valve replacement’:ti,ab OR ‘SPVR’:ti,ab OR ‘surgical mitral valve acement’:ti,ab OR ‘surgical tricuspid valve replacement’:ti,ab OR ‘homograft valve replacement’:ti,ab	96,059
5	#3 AND #4	1,482
6	T ('conference abstract'/it OR 'conference paper'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'short survey'/it)	933
7	#6 NOT 'case report'/de	701
Filters	English-language only	585

Isolated Native Endocarditis Prosthetic Valve Implantation

rall search	lve endocarditis':ti,ab OR 'nve':ti,ab OR 'native endocarditis':ti,ab OR ('native' AND ('infective arditis'/mj OR 'mitral valve endocarditis':ti,ab OR 'aortic valve endocarditis':ti,ab OR 'tricuspid docarditis':ti,ab OR 'pulmonary valve endocarditis':ti,ab OR 'pulmonic valve endocarditis':ti,ab ve endocarditis':ti,ab OR 'infectious endocarditis':ti,ab OR 'bacterial endocarditis':ti,ab))) AND e replacement'/exp/mj OR 'heart valve prosthesis'/mj OR 'aortic valve prosthesis'/mj OR 'mitral hesis'/mj OR 'pulmonary valve prosthesis'/mj OR 'tricuspid valve prosthesis'/mj OR 'prosthetic ab OR 'valve replacement':ti,ab OR 'transcatheter aortic valve replacement':ti,ab OR 'tavr':ti,ab R 'transcatheter aortic valve implantation':ti,ab OR 'tavi':ti,ab OR 'transcatheter tricuspid valve ent':ti,ab OR 'ttvr':ti,ab OR 'transcatheter pulmonary valve replacement':ti,ab OR 'tpvr':ti,ab OR nscatheter mitral valve replacement':ti,ab OR 'transcatheter mitral valve implantation':ti,ab OR aortic valve replacement':ti,ab OR 'savr':ti,ab OR 'surgical pulmonary valve replacement':ti,ab i,ab OR 'surgical mitral valve replacement':ti,ab OR 'surgical tricuspid valve replacement':ti,ab 'homograft valve replacement':ti,ab) NOT ('conference abstract'/it OR 'conference paper'/it OR itorial'/it OR 'letter'/it OR 'note'/it OR 'short survey'/it) NOT 'case report'/de AND [english]/lim

tabase	**Cochrane Library**	
Line #	**Search Terms**	**# of Results**
1	“native valve endocarditis” OR “NVE” OR “native endocarditis”	63
2	AND (“mitral valve endocarditis” OR “aortic valve endocarditis” OR “tricuspid valve ocarditis” OR “pulmonary valve endocarditis” OR “pulmonic valve endocarditis” OR “infective endocarditis” OR “infectious endocarditis” OR “bacterial endocarditis”)	25
3	#1 OR #2	82
4	e prosthesis" OR “prosthetic valve” OR “valve replacement” OR “transcatheter aortic acement” OR “TAVR” OR “transcatheter aortic valve implantation” OR “TAVI” OR atheter tricuspid valve replacement" OR "TTVR" OR “transcatheter pulmonary valve t” OR “TPVR” OR "transcatheter mitral valve replacement” OR "transcatheter mitral alve implantation” OR “surgical aortic valve replacement” OR “SAVR” OR “surgical lmonary valve replacement” OR “SPVR” OR "surgical mitral valve replacement" OR "surgical tricuspid valve replacement" OR “homograft valve replacement”	4145
5	#3 AND #4	12
Filters	English-language only	12

Isolated Native Endocarditis Prosthetic Valve Implantation

base	Web of Science	
ine #	Search Terms	# of Results
1	“native valve endocarditis” OR “NVE” OR “native endocarditis”	1,437
2	” AND (“mitral valve endocarditis” OR “aortic valve endocarditis” OR “tricuspid valve ndocarditis” OR “pulmonary valve endocarditis” OR “pulmonic valve endocarditis” OR “infective endocarditis” OR “infectious endocarditis” OR “bacterial endocarditis”)	1,480
3	#1 OR #2	2,425
4	lve prosthesis" OR “prosthetic valve” OR “valve replacement” OR “transcatheter aortic eplacement” OR “TAVR” OR “transcatheter aortic valve implantation” OR “TAVI” OR nscatheter tricuspid valve replacement" OR "TTVR" OR “transcatheter pulmonary valve ent” OR “TPVR” OR "transcatheter mitral valve replacement” OR "transcatheter mitral antation” OR “surgical aortic valve replacement” OR “SAVR” OR “surgical pulmonary placement” OR “SPVR” OR "surgical mitral valve replacement" OR "surgical tricuspid valve replacement" OR “homograft valve replacement”	49,772
5	#3 AND #4	708
lters	nguage only, document types: **Proceeding Paper**, **Editorial Material, Meeting Abstract, Letter, and Note were excluded**	566

Table 2. Summary of findings in TAVI group. Summary of categorical findings for TAVIE AND INVE in TA studies (n = 4). Missing data is marked as "unknown"

Table 2. Summary of findings in TAVI group. Summary of categorical findings for TAVIE AND INVE in TA studies (n = 4). Missing data is marked as "unknown"

Category	Panagides	Yun	Mangner	Scislo	Total
Period of study	June 2005 - Nov 2020	Jan 2012 - July 2020	June 2008 - Apr 2017	Jan 2010 - Dec 2018	—
Region	Europe, North America, and South America	Cleveland Clinic, Ohio	Heart Center Dresden, Germany	Medical University Warsaw, Poland	—
Design	Multicenter retrospective	Single-center retrospective	Single-center retrospective	Single-center retrospective	—
Total size of TAVI group	20,006	59	110	311	20486
Total # of IE cases after TAVI	568	10	61	6	645
Total # of TAVIE cases	461	8	53	4	526
Total # of INVE cases	107	2	8	2	119
Proportion INVE of all IE (%)	18.8 %	20.0 %	13.1 %	33.3 %	119/ 645 (18.4 %)
Mean age					
TAVIE	78.5 ± 7.7	70	80.2 ± 5.5	81	78.6 +- 7
INVE	79.7 ± 6.8	68.5	80.2 ± 5.5	76	79.5 +- 5
Gender					
TAVIE	Male (253)	Male (6)	Male (31)	Male (2)	292/526 (55.5 %)
INVE	Male (60)	Male (1)	Male (5)	Male (1)	67/119 (56.3 %)
Comorbidities (total #) TAVIE					
DM	129	4	25	2	160/526 (30.4 %)

Isolated Native Endocarditis Prosthetic Valve Implantation

COPD	90	5	9	2	106/526 (20.2 %)
CKD	213	1	27	2	243/526 (46.2 %)
Coronary/Peripheral artery	0	2	39	2	43/526 (8.2 %)
Atrial fibrillation	201	1	34	1	237/526 (45.1 %)
Hypertension	0	7	0	2	9/526 (1.7 %)
Stroke	38	2	5	0	45/526 (8.6 %)
Heart failure	0	0	30	0	30/526 (5.7 %)
Mitral regurgitation	134	8	Unknown	Unknown	>142/526 (>27.0 %)
Aortic regurgitation	47	8	Unknown	2	>57/526 (>10.8 %)
Tricuspid regurgitation	Unknown	5	8	Unknown	>13/526 (2.5 %)
Perivalvular leak	106	2	Unknown	4	>112/526 (21.3 %)
Valvular stenosis	0	4	Unknown	4	>8/526 (1.5 %)
Inflammatory disease	0	0	0	0	0 (0.0 %)
Pulmonary embolism	2	0	0	0	2/526 (0.4 %)
Prior endocarditis	2	Unknown	28	0	> 30/526 (> 5.7 %)
Valve surgery prior to TAVI	32	4	Unknown	0	> 36/526 (> 6.8 %)
Immunosuppression	Unknown	Unknown	10	0	> 10/526 (> 1.9 %)
Malignancy	1	Unknown	Unknown	Unknown	>1/526 (0.2 %)
INVE					
DM	41	1	5	1	48/119 (40.3 %)
COPD	31	1	3	0	35/119 (29.4 %)
CKD	34	0	4	1	39/119 (32.8 %)
Coronary/Peripheral artery	0	0	6	0	6/119 (5.0 %)
Atrial fibrillation	47	1	7	0	55/119 (46.2 %)
Hypertension	0	0	0	1	1/119 (0.8 %)
Stroke	10	0	1	0	11/119 (9.2 %)
Heart failure	0	0	6	0	6/119 (5.0 %)
Mitral regurgitation	27	2	Unknown	Unknown	>29/119 (>24.4 %)
Aortic regurgitation	28	2	Unknown	0	>30/119 (>25.2 %)
Tricuspid regurgitation	Unknown	1	1	Unknown	>2/119 (1.7 %)
Perivalvular leak	12	0	Unknown	2	>14/119 (>11.8 %)
Valvular stenosis	0	1	Unknown	2	>3/119 (>2.5 %)
Inflammatory disease	0	0	Unknown	0	Unknown
Pulmonary embolism	2	0	0	0	2/119 (1.7 %)
Prior endocarditis	3	Unknown	4	0	>7/119 (> 5.9 %)
Valve surgery prior to TAVI	15	1	Unknown	0	>16/119 (> 13.4 %)
Immunosuppression	Unknown	Unknown	1	0	>1/119 (> 0.8 %)
Malignancy	0	Unknown	Unknown	Unknown	Unknown
Antibiotic prophylaxis					
TAVIE					
Vancomycin	11	Unknown	Unknown	Unknown	> 11/ 526 (>2.1 %)
Beta lactam/cephalosporin	429	Unknown	Unknown	Unknown	> 429/526 (> 81.6 %)
Other	6	Unknown	Unknown	Unknown	> 6/526 (> 1.1 %)
INVE					
Vancomycin	8	Unknown	Unknown	Unknown	>8/119 (> 6.7 %)
Beta lactam/cephalosporin	99	Unknown	Unknown	Unknown	> 99/119 (> 83.2 %)
Other	0	Unknown	Unknown	Unknown	Unknown
TAVI access site per group					
TAVIE					
Transfemoral	397	Unknown	47	2	> 446/526 (> 84.8 %)
Transapical	Unknown	Unknown	6	0	> 6/526 (> 1.1 %)
Other	Unknown	Unknown	0	1	> 1/526 (> 0.2 %)
INVE					
Transfemoral	96	Unknown	7	2	> 105/119 (> 88.2%)
Transapical	Unknown	Unknown	1	0	> 1/119 (> 0.8 %)
Other	11	Unknown	0	0	> 11/119 (> 9.2 %)
LVEF					
TAVIE	53.2 ± 13.0	59 %	53 ± 13	25-60 %	53 +- 12.7 %
INVE	56.2 ± 11.8	59 %	53 ± 13	29-60 %	56 +- 11.5 %
Transcatheter valve type					
TAVIE					

Isolated Native Endocarditis Prosthetic Valve Implantation

Corevalve self expanding	199	2	36	2	239/526 (45.4 %)
Sapien balloon expanding	273	6	17	0	296/526 (56.3 %)
Boston Scientific Lotus	0	0	0	1	1/526 (0.2 %)
INVE					
Corevalve self expanding	37 mitral 19 right heart	2 mitral 0 right heart	7 mitral 0 right heart	2 mitral 0 right heart	+ mitral valve 48/119 (40.3 %) + right valve 19/119 (16.0 %)
Sapien balloon expanding	38 mitral 13 right heart	0	1 mitral 0 right heart	0	+ mitral valve 39/119 (32.8 %) + right valve 13/119 (10.9 %)
Boston Scientific Lotus	0	0	0	0	0/119 (0.0 %)
Causual pathogen					
TAVIE					
Staphylococcus	186	4	20	2	212/526 (40.3 %)
Streptococcus	99	2	6	1	108/526 (20.5 %)
Enterococcus	130	2	21	1	154/526 (29.3 %)
Other	54	0	6	2	62/526 (11.8 %)
INVE					
Staphylococcus	46	1	3	2	54/119 (45.4 %)
Streptococcus	27	0	1	0	28/119 (23.5 %)
Enterococcus	25	0	3	1	31/119 (26.0 %)
Other	8	1	1	0	9/119 (7.6 %)
TAVIE treatment					
Antibiotics					
Vancomycin	21	Unknown	Unknown	3	>20/526 (>3.8 %)
Beta lactam/cephalosporin	439	Unknown	Unknown	1	>345/526 (65.6 %)
Other	12	Unknown	34	3	>46/526 (8.7 %)
Surgery	102	8	19	1	130/526 (24.7 %)
INVE treatment					
Antibiotics					
Vancomycin	8	Unknown	Unknown	1	>9/119 (>7.6 %)
Beta lactam/cephalosporin	99	Unknown	Unknown	1	>100/119 (>84.0 %)
Other	0	Unknown	Unknown	2	>2/119 (>1.7 %)
Surgery	6	2	1	0	9/119 (7.6 %)
Follow up in years					
SAVIE	2	1	1	3	2
INVE	2	1	1	3	2
Total deaths (in hospital + follow up)					
TAVIE	141 in hospital 0 endocarditis 24 septic shock 38 heart failure 33 renal failure 11 system emboli 26 bacteremia 9 stroke	1 in hospital 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 1 stroke	28 in hospital 6 endocarditis 8 septic shock 3 heart failure 5 renal failure 5 system emboli 0 bacteremia 1 stroke	0 in hospital 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	170/526 (32.3 %) in hospital 9/526 (1.7 %) endocarditis 33/526 (6.3 %) septic shock 42/526 (8.0 %) heart failure 39/526 (7.4 %) renal failure 11/526 (2.1 %) systemic emboli 26/526 (4.9 %) bacteremia 11/526 (2.1 %) stroke
	96 at follow up 0 endocarditis 17 septic shock 26 heart failure 22 renal failure 7 system emboli 18 bacteremia	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	10 follow up 2 endocarditis 3 septic shock 1 heart failure 1 renal failure 3 system emboli 0 bacteremia 0 stroke	3 follow up 3 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	109/526 (20.7 %) at follow up 5/526 (1.0 %) endocarditis 20/526 (3.8 %) septic shock 27/526 (5.1 %) heart failure 23/526 (4.4 %) renal failure 10/526 (1.9 %) systemic emboli 18/526 (3.4 %) bacteremia 6/526 (1.1 %) stroke

Isolated Native Endocarditis Prosthetic Valve Implantation

	6 stroke				
INVE		0 in hospital	1 in hospital	0 in hospital	22/119 (18.5 %) in hospital
	21 in hospital	0 endocarditis	0 endocarditis	0 endocarditis	0/119 (0.0 %) endocarditis
	0 endocarditis	0 septic shock	1 septic shock	0 septic shock	6/119 (5.0 %) septic shock
	5 septic shock	0 heart failure	0 heart failure	0 heart failure	5/119 (4.2 %) heart failure
	5 heart failure	0 renal failure	0 renal failure	0 renal failure	4/119 (3.4 %) renal failure
	4 renal failure	0 system emboli	0 system emboli	0 system emboli	3/119 (2.5 %) systemic emboli
	3 system emboli	0 bacteremia	0 bacteremia	0 bacteremia	4/119 (3.4 %) bacteremia
	4 bacteremia	0 stroke	0 stroke	0 stroke	0/119 (0.0 %) stroke
	0 stroke				
		0 at follow up	4 at follow up	1 at follow up	39/119 (32.8 %) at follow up
	34 at follow up	0 endocarditis	1 endocarditis	0 endocarditis	1/119 (0.8 %) endocarditis
	0 endocarditis	0 septic shock	1 septic shock	0 septic shock	10/119 (8.4 %) septic shock
	9 septic shock	0 heart failure	0 heart failure	0 heart failure	8/119 (6.7 %) heart failure
	8 heart failure	0 renal failure	2 renal failure	1 renal failure	9/119 (7.6 %) renal failure
	6 renal failure	0 system emboli	0 system emboli	0 system emboli	5/119 (4.2 %) systemic emboli
	5 system emboli	0 bacteremia	0 bacteremia	0 bacteremia	6/119 (5.0 %) bacteremia
	6 bacteremia	0 stroke	0 stroke	0 stroke	0/119 (0.0 %) stroke
	0 stroke				

Category	Panagides	Yun	Mangner	Scislo	
Period of study	June 2005 - Nov 2020	Jan 2012 - July 2020	June 2008 - Apr 2017	Jan 2010 - Dec 2018	
Region	Europe, North America, and South America	Cleveland Clinic, Ohio	Heart Center Dresden, Germany	Medical University Warsaw, Poland	
Design	Multicenter retrospective	Single-center retrospective	Single-center retrospective	Single-center retrospective	
Total size of TAVI group	20,006	59	110	311	
Total # of IE cases after TAVI	568	10	61	6	
Total # of TAVIE cases	461	8	53	4	
Total # of INVE cases	107	2	8	2	
Proportion INVE of all IE (%)	18.8 %	20.0 %	13.1 %	33.3 %	
Mean age					
TAVIE	78.5 ± 7.7	70	80.2 ± 5.5	81	
INVE	79.7 ± 6.8	68.5	80.2 ± 5.5	76	
Gender					
TAVIE	Male (253)	Male (6)	Male (31)	Male (2)	
INVE	Male (60)	Male (1)	Male (5)	Male (1)	
Comorbidities (total #)					
TAVIE					
DM	129	4	25	2	
COPD	90	5	9	2	
CKD	213	1	27	2	
Coronary/Peripheral artery disease	0	2	39	2	
Atrial fibrillation	201	1	34	1	
Hypertension	0	7	0	2	
Stroke	38	2	5	0	
Heart failure	0	0	30	0	
Mitral regurgitation	134	8	Unknown	Unknown	
Aortic regurgitation	47	8	Unknown	2	
Tricuspid regurgitation	Unknown	5	8	Unknown	

Isolated Native Endocarditis Prosthetic Valve Implantation

Perivalvular leak	106	2	Unknown	4	
Valvular stenosis	0	4	Unknown	4	
Inflammatory disease	0	0	0	0	
Pulmonary embolism	2	0	0	0	
Prior endocarditis	2	Unknown	28	0	
Valve surgery prior to TAVI	32	4	Unknown	0	
Immunosuppression	Unknown	Unknown	10	0	
Malignancy	1	Unknown	Unknown	Unknown	
INVE					
DM	41	1	5	1	
COPD	31	1	3	0	
CKD	34	0	4	1	
Coronary/Peripheral artery disease	0	0	6	0	
Atrial fibrillation	47	1	7	0	
Hypertension	0	0	0	1	
Stroke	10	0	1	0	
Heart failure	0	0	6	0	
Mitral regurgitation	27	2	Unknown	Unknown	
Aortic regurgitation	28	2	Unknown	0	
Tricuspid regurgitation	Unknown	1	1	Unknown	
Perivalvular leak	12	0	Unknown	2	
Valvular stenosis	0	1	Unknown	2	
Inflammatory disease	0	0	Unknown	0	
Pulmonary embolism	2	0	0	0	
Prior endocarditis	3	Unknown	4	0	
Valve surgery prior to TAVI	15	1	Unknown	0	
Immunosuppression	Unknown	Unknown	1	0	
Malignancy	0	Unknown	Unknown	Unknown	
Antibiotic prophylaxis					
TAVIE					
Vancomycin	11	Unknown	Unknown	Unknown	
Beta lactam/cephalosporin	429	Unknown	Unknown	Unknown	>
Other	6	Unknown	Unknown	Unknown	
INVE					
Vancomycin	8	Unknown	Unknown	Unknown	
Beta lactam/cephalosporin	99	Unknown	Unknown	Unknown	:
Other	0	Unknown	Unknown	Unknown	
TAVI access site per group					
TAVIE					
Transfemoral	397	Unknown	47	2	>
Transapical	Unknown	Unknown	6	0	
Other	Unknown	Unknown	0	1	
INVE					
Transfemoral	96	Unknown	7	2	>
Transapical	Unknown	Unknown	1	0	
Other	11	Unknown	0	0	
LVEF					
TAVIE	53.2 ± 13.0	59 %	53 ± 13	25-60 %	

Isolated Native Endocarditis Prosthetic Valve Implantation

INVE	56.2 ± 11.8	59 %	53 ± 13	29-60 %	
Transcatheter valve type					
TAVIE					
Corevalve self expanding	199	2	36	2	
Sapien balloon expanding	273	6	17	0	
Boston Scientific Lotus	0	0	0	1	
INVE					
Corevalve self expanding	37 mitral 19 right heart	2 mitral 0 right heart	7 mitral 0 right heart	2 mitral 0 right heart	+ mitral valv + right valve
Sapien balloon expanding	38 mitral 13 right heart	0	1 mitral 0 right heart	0	+ mitral valv + right valve
Boston Scientific Lotus	0	0	0	0	
Causual pathogen					
TAVIE					
Staphylococcus	186	4	20	2	
Streptococcus	99	2	6	1	
Enterococcus	130	2	21	1	
Other	54	0	6	2	
INVE					
Staphylococcus	46	1	3	2	
Streptococcus	27	0	1	0	
Enterococcus	25	0	3	1	
Other	8	1	1	0	
TAVIE treatment					
Antibiotics					
Vancomycin	21	Unknown	Unknown	3	
Beta lactam/cephalosporin	439	Unknown	Unknown	1	
Other	12	Unknown	34	3	
Surgery	102	8	19	1	
INVE treatment					
Antibiotics					
Vancomycin	8	Unknown	Unknown	1	
Beta lactam/cephalosporin	99	Unknown	Unknown	1	
Other	0	Unknown	Unknown	2	
Surgery	6	2	1	0	
Follow up in years					
SAVIE	2	1	1	3	
INVE	2	1	1	3	
Total deaths (in hospital + follow up)					

TAVIE	141 in hospital	1 in hospital	28 in hospital	0 in hospital	170/526 (32.
	0 endocarditis	0 endocarditis	6 endocarditis	0 endocarditis	9/526
	24 septic shock	0 septic shock	8 septic shock	0 septic shock	33/526
	38 heart failure	0 heart failure	3 heart failure	0 heart failure	42/526
	33 renal failure	0 renal failure	5 renal failure	0 renal failure	39/526
	11 system emboli	0 system emboli	5 system emboli	0 system emboli	11/526 (2.1
	26 bacteremia	0 bacteremia	0 bacteremia	0 bacteremia	26/526
	9 stroke	1 stroke	1 stroke	0 stroke	1
	96 at follow up	0 at follow up	10 follow up	3 follow up	109/526 (20.
	0 endocarditis	0 endocarditis	2 endocarditis	3 endocarditis	5/526
	17 septic shock	0 septic shock	3 septic shock	0 septic shock	20/526
	26 heart failure	0 heart failure	1 heart failure	0 heart failure	27/526
	22 renal failure	0 renal failure	1 renal failure	0 renal failure	23/526
	7 system emboli	0 system emboli	3 system emboli	0 system emboli	10/526 (1.9
	18 bacteremia	0 bacteremia	0 bacteremia	0 bacteremia	18/526
	6 stroke	0 stroke	0 stroke	0 stroke	6
INVE	21 in hospital	0 in hospital	1 in hospital	0 in hospital	22/119 (18.5
	0 endocarditis	0 endocarditis	0 endocarditis	0 endocarditis	0/119
	5 septic shock	0 septic shock	1 septic shock	0 septic shock	6/119
	5 heart failure	0 heart failure	0 heart failure	0 heart failure	5/119
	4 renal failure	0 renal failure	0 renal failure	0 renal failure	4/119
	3 system emboli	0 system emboli	0 system emboli	0 system emboli	3/119 (2.5
	4 bacteremia	0 bacteremia	0 bacteremia	0 bacteremia	4/119
	0 stroke	0 stroke	0 stroke	0 stroke	0
	34 at follow up	0 at follow up	4 at follow up	1 at follow up	39/119 (32.8
	0 endocarditis	0 endocarditis	1 endocarditis	0 endocarditis	1/119
	9 septic shock	0 septic shock	1 septic shock	0 septic shock	10/119
	8 heart failure	0 heart failure	0 heart failure	0 heart failure	8/119
	6 renal failure	0 renal failure	2 renal failure	1 renal failure	9/119
	5 system emboli	0 system emboli	0 system emboli	0 system emboli	5/119 (4.2
	6 bacteremia	0 bacteremia	0 bacteremia	0 bacteremia	6/119
	0 stroke	0 stroke	0 stroke	0 stroke	0/

Table 3. Statistical comparison of categories between TAVIE and TAVIE INVE groups. Categories significant vs non-significant differences between INVE and TAVIE after chi-square analyses with odds (OR), relative risk (RR), P value, and confidence interval (CI).

Category of Interest	OR or RR	P value	CI
Comorbidity			
DM	OR = 1.55	0.037	1.03 - 2.33
COPD	OR = 1.65	0.027	1.05 - 2.58
CKD	OR = 0.57	0.008	0.37 - 0.86
Coronary/Peripheral artery disease	OR = 0.60	0.244	0.25 - 1.44
Atrial fibrillation	OR = 1.05	0.818	0.70 - 1.56
Hypertension	OR = 0.48	0.488	0.06 - 3.88

Stroke	OR = 1.09	0.810	0.55 - 2.17
Heart failure	OR = 0.88	0.777	0.35 - 2.16
Inflammatory disease	OR = N/A	N/A	N/A
Pulmonary embolism	OR = 4.48	0.103	0.62 - 32.12
Prior endocarditis	OR = 1.03	0.940	0.44 - 2.41
TAVI type			
Corevalve	OR = 1.55	0.032	1.04 - 2.31
Sapien	OR = 0.60	0.013	0.40 - 0.90
Intervention			
Surgery	RR = 0.31	< 0.001	0.16 - 0.58
Mortality location			
In hospital	RR = 0.65	0.015	0.45 - 0.94
Follow up	RR = 1.47	0.021	1.07 - 2.03
Mortality cause			
Endocarditis	RR = 0.32	0.23	0.04 - 2.4
Septic shock	RR = 1.33	0.28	0.79 - 2.25
Heart failure	RR = 0.83	0.52	0.48 - 1.46
Renal failure	RR = 0.93	0.79	0.53 - 1.63
Systemic emboli	RR = 1.68	0.19	0.76 - 3.71
Bacteremia	RR = 1.01	0.99	0.52 - 1.94
Stroke	N/A	N/A	N/A

Table 4. Summary of findings in SAVI groups . Summary of categorical findings for SAVIE populations per f
study (n = 4). Missing data is marked as "unknown" or "?"

Category	Davila	Solari	Korem	Croon	Total
Period of study	Jan 1985 - Dec 1999	Jan 1990 - Dec 2014	Jan 2009 -Oct 2011	Jan 1998 - Dec 2017	–
Region	Ramon Cajal Hospital Madrid, Spain	St Luc's Hospital, Brussels, Belgium	Hadassah-Hospital, Jerusalem, Israel	Catharina Hospital in Eindhoven, Netherlands	–
Design	Single-center retrospective	Single center cohort	Single center cohort	Single-center retrospective	–
Total size of SAVI group	Unknown	112	27	69	Unknown
Total # of IE cases after SAVI	103	5	22	8	138
Total # of SAVIE cases	100	4	18	7	129
Total # of INVE cases	3	1	4	1	9
Proportion INVE of all IE (%)	3/103 (2.9 %)	1/5 (20 %)	4/22 (18.2 %)	1/8 (25 %)	9/138 (6.5 %)
Mean age + standard deviation					
SAVIE	59.3 ± 17.9	58.5 ± 13.6	64.3 ± 7.1	58 ± 15	59.9 ± 15.8
INVE	68.7	58.5	64.2	58	64.4 ± 3.8
Gender					
SAVIE	Male (46)	Male (4)	Male (10)	Male (6)	66/129 (51.2 %)
INVE	Male (3)	Male (1)	Male (3)	Male (1)	8/9 (88.9 %)
Number of Comorbidities					
SAVIE					
DM	Unknown	0	7	1	>8/129 (> 6.2 %)
COPD	Unknown	0	0	1	>1/129 (> 0.8 %)

CKD	Unknown	0	0	2	>2/129 (>1.6 %)
Coronary/Peripheral artery	Unknown	0	0	1	>1/129 (> 0.8 %)
Atrial fibrillation	Unknown	0	0	0	Unknown
Hypertension	Unknown	0	0	2	>2/129 (> 1.6 %)
Stroke	Unknown	0	0	1	>1/129 (> 0.8 %)
Heart failure	Unknown	1	10	1	>12/129 (> 9.3 %)
Malignancy	Unknown	0	4	0	>4/129 (> 3.1 %)
Mitral regurgitation	Unknown	0	1	0	>1/129 (>0.8%)
Aortic regurgitation	Unknown	4	1	0	>5/129 (>3.9 %)
Perivalvular leak	Unknown	0	0	0	Unknown
Valvular stenosis	Unknown	0	0	0	Unknown
Inflammatory disease	Unknown	0	0	0	Unknown
Pulmonary embolism	Unknown	0	0	0	Unknown
Prior endocarditis	Unknown	4	3	8	>15/129 (>11.6 %)
Prior valve surgery	6	2	0	8	16/129 (12.4 %)
Immunosuppression	Unknown	0	0	0	Unknown
Malignancy	Unknown	0	4	0	>4/129 (>3.2 %)
INVE					
DM	Unknown	0	2	0	>2/9 (>22.2 %)
COPD	Unknown	0	0	0	Unknown
CKD	Unknown	0	0	0	Unknown
Coronary/Peripheral artery	Unknown	0	0	0	Unknown
Atrial fibrillation	Unknown	0	0	0	Unknown
Hypertension	Unknown	0	0	1	>1/9 (> 11.1 %)
Stroke	Unknown	0	0	0	Unknown
Heart failure	1	0	1	0	2/9 (22.2 %)
Mitral regurgitation	Unknown	0	3	0	>3/9 (> 33.3 %)
Aortic regurgitation	Unknown	1	2	0	>3/9 (>33.3 %)
Perivalvular leak	Unknown	0	0	0	Unknown
Valvular stenosis	Unknown	0	0	0	Unknown
Inflammatory disease	1	0	0	0	1/9 (11.1 %)
Pulmonary embolism	Unknown	0	0	0	Unknown
Prior endocarditis	Unknown	1	0	0	>1/9 (>11.1 %)
Prior valve surgery	0	0	0	0	0/9 (0.0 %)
Immunosuppression	Unknown	0	0	0	Unknown
Malignancy	Unknown	0	1	0	>1/9 (>11.1 %)
Antibiotic prophylaxis					
SAVIE					
Vancomycin	Unknown	Unknown	Unknown	Unknown	Unknown
Beta lactam/cephalosporin	Unknown	Unknown	Unknown	Unknown	Unknown
Other	Unknown	Unknown	Unknown	Unknown	Unknown
INVE					
Vancomycin	Unknown	Unknown	Unknown	Unknown	Unknown
Beta lactam/cephalosporin	Unknown	Unknown	Unknown	Unknown	Unknown
Other	Unknown	Unknown	Unknown	Unknown	Unknown
Surgical valve type + location of IE if INVE					
SAVIE					
Mechanical	Unknown	0	Unknown	Unknown	Unknown
Biologic					
Bovine	Unknown	0	Unknown	Unknown	Unknown
Porcine	Unknown	0	Unknown	Unknown	Unknown
Homograft	0	4	0	0	4/129 (3.1 %)
Other	Unknown	0	Unknown	Unknown	Unknown
INVE					

Isolated Native Endocarditis Prosthetic Valve Implantation

Mechanical	0 mitral 0 right heart	0 mitral 0 right heart	Unknown	Unknown	+ mitral valve Unknown + right valve Unknown
Biologic					
Bovine	0 mitral 0 right heart	0 mitral 0 right heart	Unknown	1 mitral 0 right heart	+ mitral valve 1/9 (11.1 %) + right valve Unknown
Porcine	0 mitral 0 right heart	0 mitral 0 right heart	Unknown	Unknown	+ mitral valve Unknown + right valve Unknown
Homograft	0 mitral 0 right heart	1 mitral 0 right heart	0 mitral 0 right heart	0 mitral 0 right heart	+ mitral valve 1/9 (11.1 %) + right valve 0/9 (0.0 %)
Unknown	2 mitral 1 tricuspid	0 mitral 0 tricuspid	4 mitral 0 tricuspid	0 mitral 0 tricuspid	+ mitral valve 6/9 (66.7 %) + tricuspid valve 1/9 (11.1%)
Pathogen					
SAVIE					
Staphylococcus	48	1	6	2	57/129 (44.2 %)
Streptococcus	15	1	2	2	20/129 (15.5 %)
Enterococcus	9	0	3	0	12/129 (9.3 %)
Other	28	2	7	3	40/129 (31.0 %)
INVE					
Staphylococcus	2	1	1	1	5/9 (55.6 %)
Streptococcus	0	0	1	0	1/9 (11.1 %)
Enterococcus	1	0	1	0	2/9 (22.2 %)
Other	0	0	1	0	1/9 (11.1 %)
SAVIE treatment					
Antibiotics					
Vancomycin	0	0	0	0	0 (0 %)
Beta lactam/cephalosporin	0	0	0	0	0 (0 %)
Other	71	1	14	0	86/129 (66.7 %)
Surgery	29	3	4	7	43/129 (33.3 %)
INVE treatment					
Antibiotics					
Vancomycin	0	0	0	0	0 (0 %)
Beta lactam/cephalosporin	0	0	0	0	0 (0 %)
Other	2	1	4	1	8/9 (88.9 %)
Surgery	1	0	0	0	1/9 (11.1 %)
Follow up in years					
SAVIE	8.5	20	0.5	10	7.8
INVE	8.5	20	0.5	10	7.8
Total deaths (in hospital + follow up)					
SAVIE	11 in hospital 6 endocarditis 0 septic shock 1 heart failure 0 renal failure 3 system emboli 0 bacteremia 1 stroke	0 in hospital 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	9 in hospital 0 endocarditis 0 septic shock 4 heart failure 0 renal failure 3 system emboli 0 bacteremia 2 stroke	4 in hospital 4 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	24/129 (18.6 %) in hospital only 10/129 (7.8 %) endocarditis 0/129 (0.0 %) septic shock 5/129 (3.9 %) heart failure 0/129 (0.0 %) renal failure 6/129 (4.7 %) systemic emboli 0/129 (0.0 %) bacteremia 3/129 (2.3 %) stroke
	6 at follow up 3 endocarditis 0 septic shock 2 heart failure 0 renal failure 1 system emboli 0 bacteremia 0 stroke	1 at follow up 0 endocarditis 1 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	1 at follow up ? endocarditis ? septic shock ? heart failure ? renal failure ? system emboli ? bacteremia ? stroke	8/129 (7.0 %) follow up only >3/129 (> 2.3 %) endocarditis >1/129 (> 0.8 %) septic shock >2/129 (> 1.6 %) heart failure >1/129 (> 0.8 %) renal failure >1/129 (> 0.8 %) system emboli ?/129 (? %) bacteremia ?/129 (? %) stroke

Isolated Native Endocarditis Prosthetic Valve Implantation

INVE	1 in hospital 0 endocarditis 0 septic shock 1 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 in hospital 0 endocarditis 0 septic shock 1 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	1 in hospital 0 endocarditis 0 septic shock 0 heart failure 1 renal failure 0 system emboli 0 bacteremia 0 stroke	0 in hospital 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	2/9 (22.2 %) in hospital only 0/9 (11.1 %) endocarditis 0/9 (0.0 %) septic shock 2/9 (22.2 %) heart failure 1/9 (0.0 %) renal failure 0/9 (0.0 %) systemic emboli 0/9 (0.0 %) bacteremia 0/9 (0.0 %) stroke
	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 at follow up ? endocarditis ? septic shock ? heart failure ? renal failure ? system emboli ? bacteremia ? stroke	0/9 (0.0 %) follow up only ?/9 (0.0 %) endocarditis ?/9 (0.0 %) septic shock ?/9 (0.0 %) heart failure ?/9 (0.0 %) renal failure ?/9 (0.0 %) systemic emboli ?/9 (0.0 %) bacteremia ?/9 (0.0 %) stroke

Category	Davila	Solari	Korem	Croon	T
Period of study	Jan 1985 - Dec 1999	Jan 1990 - Dec 2014	Jan 2009 -Oct 2011	Jan 1998 - Dec 2017	
Region	Ramon Cajal Hospital Madrid, Spain	St Luc's Hospital, Brussels, Belgium	Hadassah-Hospital, Jerusalem, Israel	Catharina Hospital in Eindhoven, Netherlands	
Design	Single-center retrospective	Single center cohort	Single center cohort	Single-center retrospective	
Total size of SAVI group	Unknown	112	27	69	
Total # of IE cases after SAVI	103	5	22	8	
Total # of SAVIE cases	100	4	18	7	
Total # of INVE cases	3	1	4	1	
Proportion INVE of all IE (%)	2.9 %	20 %	18.2 %	25 %	
Mean age + standard deviation SAVIE INVE	 59.3 ± 17.9 68.7	 58.5 ± 13.6 58.5	 64.3 ± 7.1 64.2	 58 ± 15 58	
Gender SAVIE INVE	 Male (46) Male (3)	 Male (4) Male (1)	 Male (10) Male (3)	 Male (6) Male (1)	
Number of Comorbidities SAVIE					
DM	Unknown	0	7	1	
COPD	Unknown	0	0	1	
CKD	Unknown	0	0	2	
Coronary/Peripheral artery disease	Unknown	0	0	1	
Atrial fibrillation	Unknown	0	0	0	
Hypertension	Unknown	0	0	2	
Stroke	Unknown	0	0	1	
Heart failure	Unknown	1	10	1	
Malignancy	Unknown	0	4	0	
Mitral regurgitation	Unknown	0	1	0	
Aortic regurgitation	Unknown	4	1	0	

Isolated Native Endocarditis Prosthetic Valve Implantation

Perivalvular leak	Unknown	0	0	0	
Valvular stenosis	Unknown	0	0	0	
Inflammatory disease	Unknown	0	0	0	
Pulmonary embolism	Unknown	0	0	0	
Prior endocarditis	Unknown	4	3	8	
Prior valve surgery	6	2	0	8	
Immunosuppression	Unknown	0	0	0	
Malignancy	Unknown	0	4	0	
INVE					
DM	Unknown	0	2	0	
COPD	Unknown	0	0	0	
CKD	Unknown	0	0	0	
Coronary/Peripheral artery disease	Unknown	0	0	0	
Atrial fibrillation	Unknown	0	0	0	
Hypertension	Unknown	0	0	1	
Stroke	Unknown	0	0	0	
Heart failure	1	0	1	0	
Mitral regurgitation	Unknown	0	3	0	
Aortic regurgitation	Unknown	1	2	0	
Perivalvular leak	Unknown	0	0	0	
Valvular stenosis	Unknown	0	0	0	
Inflammatory disease	1	0	0	0	
Pulmonary embolism	Unknown	0	0	0	
Prior endocarditis	Unknown	1	0	0	
Prior valve surgery	0	0	0	0	
Immunosuppression	Unknown	0	0	0	
Malignancy	Unknown	0	1	0	
Antibiotic prophylaxis					
SAVIE					
Vancomycin	Unknown	Unknown	Unknown	Unknown	
Beta lactam/cephalosporin	Unknown	Unknown	Unknown	Unknown	
Other	Unknown	Unknown	Unknown	Unknown	
INVE					
Vancomycin	Unknown	Unknown	Unknown	Unknown	
Beta lactam/cephalosporin	Unknown	Unknown	Unknown	Unknown	
Other	Unknown	Unknown	Unknown	Unknown	
Surgical valve type + location of IE if INVE					
SAVIE					
Mechanical	Unknown	0	Unknown	Unknown	
Biologic					
Bovine	Unknown	0	Unknown	Unknown	
Porcine	Unknown	0	Unknown	Unknown	
Homograft	0	4	0	0	
Other	Unknown	0	Unknown	Unknown	

Isolated Native Endocarditis Prosthetic Valve Implantation

INVE					
Mechanical	0 mitral 0 right heart	0 mitral 0 right heart	Unknown	Unknown	+ mitr + rig
Biologic					
Bovine	0 mitral 0 right heart	0 mitral 0 right heart	Unknown	1 mitral 0 right heart	+ mitral + righ
Porcine	0 mitral 0 right heart	0 mitral 0 right heart	Unknown	Unknown	+ mit + rig
Homograft	0 mitral 0 right heart	1 mitral 0 right heart	0 mitral 0 right heart	0 mitral 0 right heart	+ mitral + right
Unknown	2 mitral 1 tricuspid	0 mitral 0 tricuspid	4 mitral 0 tricuspid	0 mitral 0 tricuspid	+ mitral + tricuspid
Pathogen					
SAVIE					
Staphylococcus	48	1	6	2	
Streptococcus	15	1	2	2	
Enterococcus	9	0	3	0	
Other	28	2	7	3	
INVE					
Staphylococcus	2	1	1	1	
Streptococcus	0	0	1	0	
Enterococcus	1	0	1	0	
Other	0	0	1	0	
SAVIE treatment					
Antibiotics					
Vancomycin	0	0	0	0	
Beta lactam/cephalosporin	0	0	0	0	
Other	71	1	14	0	
Surgery	29	3	4	7	
INVE treatment					
Antibiotics					
Vancomycin	0	0	0	0	
Beta lactam/cephalosporin	0	0	0	0	
Other	2	1	4	1	
Surgery	1	0	0	0	
Follow up in years					
SAVIE	8.5	20	0.5	10	
INVE	8.5	20	0.5	10	
Total deaths (in hospital + follow up)					
SAVIE	11 in hospital 6 endocarditis	0 in hospital 0 endocarditis	9 in hospital 0 endocarditis	4 in hospital 4 endocarditis	24/129 (18.6 10/129 (

Isolated Native Endocarditis Prosthetic Valve Implantation

	0 septic shock 1 heart failure 0 renal failure 3 system emboli 0 bacteremia 1 stroke	0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 septic shock 4 heart failure 0 renal failure 3 system emboli 0 bacteremia 2 stroke	0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0/129 (5/129 (0/129 (6/129 (4.7 % 0/129 3/
	6 at follow up 3 endocarditis 0 septic shock 2 heart failure 0 renal failure 1 system emboli 0 bacteremia 0 stroke	1 at follow up 0 endocarditis 1 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	1 at follow up ? endocarditis ? septic shock ? heart failure ? renal failure ? system emboli ? bacteremia ? stroke	8/129 (7.0 >3/129 (> 2 >1/129 (> (>2/129 (> 1 >1/129 (> (>1/129 (> 0.8 ?/12
INVE	1 in hospital 0 endocarditis 0 septic shock 1 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 in hospital 0 endocarditis 0 septic shock 1 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	1 in hospital 0 endocarditis 0 septic shock 0 heart failure 1 renal failure 0 system emboli 0 bacteremia 0 stroke	0 in hospital 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	2/9 (22.2 0/9 (1 0/9 (2/9 (2 1/9 (0/9 (0.0 % 0/9
	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 at follow up 0 endocarditis 0 septic shock 0 heart failure 0 renal failure 0 system emboli 0 bacteremia 0 stroke	0 at follow up ? endocarditis ? septic shock ? heart failure ? renal failure ? system emboli ? bacteremia ? stroke	0/9 (0.0 ?/9 (?/9 (?/9 (?/9 (?/9 (0.0 % ?/9



Figure 1. Prisma Search. Search results generated from Covidence using PRISMA protocol. Breakdown o results from four databases and criteria used to acquire final studies for review (n = 16)